Last updated: 2026-09-08 10:29:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BeyondSpring Inc. (BYSI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.60, with a market capitalization of $25.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.57 to $2.44. This page covers its latest market performance, valuation, price trends and company information.
$25.42M | |
$0.60 | |
$48.49 | |
$0.54 | |
-- | |
74.00 | |
677.00K | |
-- | |
$2.44 | |
$0.57 | |
-- | |
-- |
BeyondSpring Inc. (BYSI) is trading at $0.65 in pre-market trading as of 2026-09-08 10:22:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing BYSI before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, BeyondSpring Inc. (BYSI) moved from $0.64 to $0.60, representing a decline of 6.28% ($0.04).
The stock traded between $0.57 and $0.70 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 90.19 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.8%
BYSI is currently trading at $0.60, placing it 1.8% of the way from its 52-week low of $0.57 to its 52-week high of $2.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BeyondSpring Inc. (BYSI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.